Tag Archives: BIO Investor Forum

BIO Investor Forum Company Snapshot: Protagonist Therapeutics

Protagonist

In our final Investor Forum Company Snapshot, we’ve profiled one of the Discovery Companies who will be presenting at the event. Protagonist Therapeutics shares their take on funding challenges and upcoming priorities, plus interesting facts about their company. Don’t miss their presentation first thing Tuesday morning! Company Snapshot What are the short-term and long-term priorities for your company? Protagonist is a peptide therapeutics based technology platform company. Short term priority:  Secure a second collaboration and Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Investor Forum Company Snapshot: Immune Design

immunedesign

In the third installment of the Investor Forum Company Snapshots, hear from Immune Design Corp. The CEO of the company, Dr. Carlos Paya, will be presenting next week at the 10th Annual BIO Investor Forum on Tuesday afternoon. Company Snapshot What are the short-term and long-term priorities for your company? Short term: focus on validating in patients a product from each of our two novel technologies.  We will be conducting testing of : 1) An Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Perspective on Market Valuation for Biotech Drug Developers

Graph

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% are working on molecular tools, diagnostics, biofuels, and other biotech endeavors. One question that is often asked with respect to drug-focused biotechs is: How big are they compared to traditional pharmaceutical companies? How many are valued as small start-ups vs large, or mid-size pharmas? It turns out that more than half the sector trades with a market valuation of less Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Technology Transfer Symposium in San Francisco

5616315608_dd9b7a55dd_b

In the midst of turbulent economic times, and at a moment when the U.S. is looking to encourage technology job creation in the coming decade, an increasing number of public and private sector initiatives have been proposed to spur job creation. While the U.S. leads in the area of biotechnology, there is no guarantee that this competitive edge will continue.  Moreover, although the U.S. is more prolific in life science discoveries than any other single country in the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Investor Forum Company Snapshot: Syndax Pharmaceuticals

Syndax

Next up in our Company Snapshot segment for the BIO Investor Forum is another presenting company of the event. Hear from Joanna Horobin, President & CEO of Syndax Pharmaceuticals, Inc. Company Snapshot What are the short-term and long-term priorities for your company? Near-term we are focused on moving our lead product candidate, entinostat, in to a phase 3 clinical trial for post-menopausal women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC). Long-term our goal is Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,